Sanofi, Innate Pharma Agree to Develop Tumor Treatment
January 11 2016 - 2:21AM
Dow Jones News
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi S.A.(SAN.FR) said
Monday it sealed an agreement with Innate Pharma S.A.(IPH.FR) to
develop a new treatment for tumors.
The two companies will work on developing new bispecific
antibody formats that engage natural killer cells to kill tumor
cells, Sanofi said in a statement.
Under the terms of the agreement, Sanofi will be responsible for
the development, manufacturing and commercialization of the
products resulting from the research collaboration.
Innate Pharma could get as much as 400 million euros ($437
million) in development and commercial milestone payments as well
as royalties on net sales, Sanofi said.
Separately, the French pharmaceutical giant said it sealed
another agreement with privately held Warp Drive Bio to develop
oncology treatment. Warp Drive Bio would be eligible to receive
more than $750 million from Sanofi, including an equity
investment.
Sanofi is rushing to develop new drugs to replace a number of
its existing drugs that are entering the public domain, which would
allow generic pharmaceutical groups to produce and sell the same
drugs at a fraction of Sanofi's price, a phenomenon known as the
"patent cliff".
Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
January 11, 2016 02:06 ET (07:06 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024